Palliative sedation therapy does not hasten death: Results from a prospective multicenter study

M. Maltoni, C. Pittureri, E. Scarpi, L. Piccinini, F. Martini, P. Turci, L. Montanari, O. Nanni, D. Amadori

Research output: Contribution to journalArticlepeer-review


Background: Palliative sedation therapy (PST) is indicated for and used to control refractory symptoms in cancer patients undergoing palliative care. We aimed to evaluate whether PST has a detrimental effect on survival in terminally ill patients. Methods: This multicenter, observational, prospective, nonrandomized population-based study evaluated overall survival in two cohorts of hospice patients, one submitted to palliative sedation (A) and the other managed as per routine hospice practice (B). Cohorts were matched for age class, gender, reason for hospice admission, and Karnofsky performance status. Results: Of the 518 patients enrolled, 267 formed cohort A and 251 cohort B. In total, 25.1% of patients admitted to the participating hospices received PST. Mean and median duration of sedation was 4 (standard deviation 6.0) and 2 days (range 0-43), respectively. Median survival of arm A was 12 days [90% confidence interval (CI) 10-14], while that of arm B was 9 days (90% CI 8-10) (log rank = 0.95, P = 0.330) (unadjusted hazard ratio = 0.92, 90% CI 0.80-1.06). Conclusion: PST does not shorten life when used to relieve refractory symptoms and does not need the doctrine of double effect to justify its use from an ethical point of view.

Original languageEnglish
Pages (from-to)1163-1169
Number of pages7
JournalAnnals of Oncology
Issue number7
Publication statusPublished - 2009


  • End-of-life care
  • Hospice
  • Palliative sedation
  • Refractory symptom
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology


Dive into the research topics of 'Palliative sedation therapy does not hasten death: Results from a prospective multicenter study'. Together they form a unique fingerprint.

Cite this